Synthesis, biological evaluation, Structure - Activity relationship studies of quinoline-imidazole derivatives as potent antimalarial agents. 2022

Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
Medicinal and Process Chemistry Division and CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India; Department of Chemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, UP, India.

In our efforts to identify novel chemical scaffolds for the development of antimalarial agents, a series of quinoline - imidazole hybrid compounds were synthesized and their blood-stage antimalarial activity was evaluated in both drug-sensitive and -multi drug-resistant (MDR) P. falciparum strains. The new analogs possess sub-micromolar activities against Plasmodium falciparum. Among all synthesized derivatives, 11(xxxii) exhibited significant antimalarial efficacy in-vitro against both CQ-sensitive (IC50-0.14 μM) and MDR strain (IC50- 0.41 μM) with minimal cytotoxicity and high selectivity. Structure-activity relationships revealed that Br and OMe substitutions on quinoline ring improved the antimalarial activity and selectivity index. The role of stereochemistry in the inhibitory activity was assessed by enantiomeric separation of a racemic mixture of 11(xxxii). The enantiomer (-)-11(xxxii) had potent antimalarial activity over the other isomer, with IC50 of 0.10 µM.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D009593 Nitroimidazoles IMIDAZOLES having a nitro moiety. Nitroimidazole
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011804 Quinolines
D006912 Hydroxyquinolines The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses. Quinolinols,Chiniofon
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D058888 14-alpha Demethylase Inhibitors Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism. 14alpha-Demethylase Inhibitors,CYP51 Inhibitors,Lanosterol 14 alpha-Demethylase Inhibitors,14 alpha Demethylase Inhibitors,14alpha Demethylase Inhibitors,Inhibitors, 14-alpha Demethylase,Inhibitors, 14alpha-Demethylase,Inhibitors, CYP51,Lanosterol 14 alpha Demethylase Inhibitors
D065692 Cytochrome P-450 CYP3A Inhibitors Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. CYP3A Inhibitor,CYP3A5 Inhibitor,CYP3A7 Inhibitor,Cyp3A4 Inhibitor,Cytochrome P-450 CYP3A Inhibitor,Cytochrome P-450 CYP3A4 Inhibitor,Cytochrome P-450 CYP3A5 Inhibitor,Cytochrome P-450 CYP3A7 Inhibitor,P450 CYP3A Inhibitor,P450 CYP3A4 Inhibitor,P450 CYP3A5 Inhibitor,P450 CYP3A7 Inhibitor,CYP3A Inhibitors,CYP3A4 Inhibitors,CYP3A5 Inhibitors,CYP3A7 Inhibitors,Cytochrome P-450 CYP3A4 Inhibitors,Cytochrome P-450 CYP3A5 Inhibitors,Cytochrome P-450 CYP3A7 Inhibitors,P450 CYP3A Inhibitors,P450 CYP3A4 Inhibitors,P450 CYP3A5 Inhibitors,P450 CYP3A7 Inhibitors,CYP3A Inhibitor, P450,CYP3A4 Inhibitor, P450,CYP3A5 Inhibitor, P450,CYP3A5 Inhibitors, P450,CYP3A7 Inhibitor, P450,CYP3A7 Inhibitors, P450,Cytochrome P 450 CYP3A Inhibitor,Cytochrome P 450 CYP3A Inhibitors,Cytochrome P 450 CYP3A4 Inhibitor,Cytochrome P 450 CYP3A4 Inhibitors,Cytochrome P 450 CYP3A5 Inhibitor,Cytochrome P 450 CYP3A5 Inhibitors,Cytochrome P 450 CYP3A7 Inhibitor,Cytochrome P 450 CYP3A7 Inhibitors,Inhibitor, CYP3A,Inhibitor, CYP3A5,Inhibitor, CYP3A7,Inhibitor, Cyp3A4,Inhibitor, P450 CYP3A,Inhibitor, P450 CYP3A4,Inhibitor, P450 CYP3A5,Inhibitor, P450 CYP3A7,Inhibitors, CYP3A,Inhibitors, CYP3A4,Inhibitors, CYP3A5,Inhibitors, CYP3A7,Inhibitors, P450 CYP3A,Inhibitors, P450 CYP3A4,Inhibitors, P450 CYP3A7

Related Publications

Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
January 2017, Bioorganic & medicinal chemistry,
Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
July 2016, Molecules (Basel, Switzerland),
Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
January 2013, Current medicinal chemistry,
Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
March 2008, Journal of medicinal chemistry,
Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
January 2023, SAR and QSAR in environmental research,
Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
August 2013, Bioorganic & medicinal chemistry letters,
Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
November 2016, Chemical biology & drug design,
Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
August 2012, European journal of medicinal chemistry,
Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
March 2008, Journal of medicinal chemistry,
Deblina Roy, and Mohammad Anas, and Ashan Manhas, and Satyen Saha, and Niti Kumar, and Gautam Panda
April 2012, ChemMedChem,
Copied contents to your clipboard!